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Key messages and recommendations 
 This population-based study documents BNT162b2 vaccine protection week-by-week after the first dose. 
 75% of protection against infection and disease is reached 15-21 days after the first dose. 
 Protection increased most rapidly against hospitalization and death and slowest against B.1.351 infection. 
 While protection of one dose beyond 21 days could not be assessed, findings support delaying the second vaccine dose in 



















Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether 
delaying administration of the second vaccine dose to vaccinate the largest number of people in the shortest time, in situations of 
limited vaccine supplies and high incidence, could avert more disease cases, hospitalizations, and deaths than the current protocol of a 
second dose shortly after the first dose. 
BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 
Qatar was recently reported with focus on individuals who completed 14 days after the second dose.
1
 Here, we provide a follow-up 
analysis of how vaccine protection develops week-by-week after the first dose. 
Data for SARS-CoV-2 were extracted from Qatar’s nationwide digital-health information platform. The platform hosts the national 
centralized SARS-CoV-2 databases that captured all vaccination records, polymerase-chain-reaction (PCR) testing, and COVID-19 
hospitalizations and deaths since epidemic start.
1
 The study was conducted from February 1-March 31, 2021, the period of rapid mass 
vaccination scale-up. Vaccine effectiveness was estimated using the test-negative case-control study design.
2
 Cases and controls were 
matched one-to-one by age, sex, nationality, and reason for PCR testing. Effectiveness was estimated against documented infection 
with the B.1.1.7 or B.1.351 variants, as well as against severe, critical, or fatal disease due to any SARS-CoV-2 infection. 
Classification of COVID-19 case severity (acute-care hospitalizations),
3
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Between February 1-March 31, 2021, 333,764 individuals received at least one BNT162b2 vaccine dose, of whom 250,619 completed 
two doses. Two-thirds (60.8%) of those vaccinated were men, and the median age was 40 years. Median time elapsed between the first 
and second doses was 21 days, and 98.4% of individuals received their second dose ≤25 days after the first dose. Effectiveness against 
infection with B.1.1.7 or B.1.351 was negligible for two weeks after the first dose (Figure 1). Effectiveness increased rapidly during 
the third week to 65.5% (95% CI: 58.2-71.5) against B.1.1.7 and 46.5% (95% CI: 38.7-53.3) against B.1.351 (Table 1). Eventually, 
≥14 days after the second dose, effectiveness reached 89.5% (95% CI: 85.9-92.3) against B.1.1.7 and 75.0% (95% CI: 70.5-78.9) 
against B.1.351. 
Effectiveness against severe, critical, or fatal disease (predominantly due to B.1.1.7 and B.1.351
5
) was negligible during the first week, 
reached 26.4% (95% CI: 0.0-49.9) in the second week, and grew to 73.2% (95% CI: 56.8-84.0) in the third week (Table 1). 
Eventually, ≥14 days after the second dose, effectiveness reached 97.4% (95% CI: 92.2-99.5). 
Development of protection against infection and disease accelerated in the third week after the first dose, right before the second dose, 
reaching nearly 75% of the value attained ≥14 days after the second dose. Protection increased most rapidly against hospitalization 
and death and slowest against B.1.351 infection. While protection of one dose beyond 21 days could not be assessed, and existing 
protocol requires a second dose for optimal protection, these findings support the strategy of delaying the second dose to vaccinate the 
largest number of people in the shortest time, in situations of limited vaccine supplies and high incidence, given the substantial 
protection achieved after only one dose. In areas where B.1.351 is at high incidence, delivering the second vaccine dose at 3-6 weeks 







































Figure 1. The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) effectiveness against infection and against disease in the 
weeks following the first dose. Error bars indicate the 95% confidence intervals for vaccine effectiveness estimates. 
 
 
Table 1. The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) effectiveness against infection and against disease in the weeks 
following vaccination with the first dose. 













in %  
(95% CI)* Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated 
Effectiveness against infection 
Any infection with the B.1.1.7 
variant† 
279 17,262 309 17,232 9.9 
(0.0-23.7) 
346 17,331 384 17,293 10.1 
(0.0-22.6) 
Any infection with the B.1.351 
variant‡ 
276 19,071 276 19,071 0.0 
(0.0-15.8) 
526 19,247 470 19,303 0.0 
(0.0-1.2) 
Effectiveness against disease 
Any severe, critical, or fatal 
disease with the B.1.1.7 variant§ 
12 431 19 424 37.9 
(0.0-72.8) 
9 426 14 421 36.5 
(0.0-76.0) 
Any severe, critical, or fatal 
disease with the B.1.351 variant¶ 
16 321 6 331 0.0 
(0.0-0.0) 
17 322 6 333 0.0 
(0.0-0.0) 
Any severe, critical, or fatal 
disease with any SARS-CoV-2 
infection** 
49 1,807 44 1,812 0.0 
(0.0-27.6) 
52 1,831 70 1,813 26.4 
(0.0-49.9) 













in %  
(95% CI)* Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated 
Effectiveness against infection 
Any infection with the B.1.1.7 
variant† 
148 17,380 422 17,106 65.5 
(58.2-71.5) 
50 16,354 465 15,939 89.5 
(85.9-92.3) 
Any infection with the B.1.351 
variant‡ 
338 19,400 623 19,115 46.5 
(38.7-53.3) 
179 19,396 698 18,877 75.0 
(70.5-78.9) 
Effectiveness against disease 
Any severe, critical, or fatal 
disease with the B.1.1.7 variant§ 
7 434 24 417 72.0 
(32.0-90.0) 
0 401 20 381 100.0 
(81.7-100.0) 
Any severe, critical, or fatal 
disease with the B.1.351 variant¶ 
9 336 20 325 56.5 
(0.0-82.8) 
0 300 14 286 100.0 
(73.7-100.0) 
Any severe, critical, or fatal 
disease with any SARS-CoV-2 
infection** 
23 1,845 83 1,785 73.2 
(56.8-84.0) 



















*Vaccine effectiveness was estimated using the test-negative, case-control study design.2 Cases and controls were matched one-to-one by age, sex, nationality, and reason for polymerase chain reaction (PCR) testing. Vaccine 
effectiveness is given by2 vaccinated among cases  unvaccinated among controlsVaccine effectiveness 1





†Any B.1.1.7 PCR-confirmed infection. A B.1.1.7 infection is proxied as an S-gene “target failure” case using the TaqPath COVID-19 Combo Kit platform (Thermo Fisher Scientific, USA), applying the criterion of PCR cycle 
threshold value ≤30 for both the N and ORF1ab genes, but a negative outcome for the S-gene. The median date of vaccination was March 1 for the cases and February 28 for their matched controls.  
‡Any B.1.351 PCR-confirmed infection. With only B.1.351 and B.1.1.7 cases identified in the viral genome sequencing after March 7, 2021, a B.1.351 infection is proxied as the complement of the B.1.1.7 criterion, that is any 
infection with a Ct value ≤30 for the N, ORF1ab, and S genes between March 8-31. The median date of vaccination was March 7 for the cases and March 1 for their matched controls. 
§Any B.1.1.7 PCR-confirmed infection that led to severe, critical, or fatal disease. Severe disease, critical disease, and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 
infection severity3 and COVID-19-related death.4  
¶Any B.1.351 PCR-confirmed infection that led to severe, critical, or fatal disease. Severe disease, critical disease, and COVID-19 death were defined based on the World Health Organization criteria for classifying SARS-CoV-2 
infection severity3 and COVID-19-related death.4  
**Any PCR-confirmed infection that led to severe, critical, or fatal disease. With the dominance of both B.1.1.7 and B.1.351 variants during the study period, this effectiveness is a combined measure against both of these variants. 
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